Join us on Facebook
Organizational
Gerald BatistProfessorOncology
Minda de Gunzburg Chair in Oncology Address:
Jewish General Hospital Telephone:
|
|
|
Education:
|
|
|
Clinical Focus:
|
|
|
Research Focus:
| |
|
Recent Presentations: "Personalized Medicine and Molecular Signatures". University of Sherbrooke, ORTI-2009 Symposium on Novel Cancer Therapeutrics, 2009.
"Novel Uses of Anthracyclines in the Elderly". Société Internationale pour l’Oncologie Gériatriqe, 2009. "Personalized Medicine through Biomarker-Driven Clinical Studies". 7th Annual McGill Symposium on Hepatobiliary Therapy, Montreal, 2009. "Personalized Medicine in Cancer Therapeutics". Hadassah Hospital, Ein Kerem Israel, 2009. "Novel paradigms in Biomarker Research: Using Clinical Trials for Discovery Research". Weizzman Institute, Rehovot Israel, 2009. "Overview of Breast Cancer Therapeutics: Deconstructing a Tissue Diagnosis into a Molecular Signature, and the Therapeutic Implications". Montreal International Symposium on Angiogenesis and Metastasis, 2009.
"Research Strategy Consultation Conference". Montreal, Canadian Cancer Research Alliance, 2009. |
|
|
Recent Publications: Puts MT, Monette J, Girre V, Costa-Lima B, Wolfson C, Batist G, Bergman H. Potential medication problems in older newly diagnosed cancer patients in canada during cancer treatment: a prospective pilot cohort study. Drugs Aging. 2010 Jul 1;27(7):559-72. doi: 10.2165/11537310-000000000-00000 Kandouz M, Batist G Gap junctions and connexins as therapeutic targets in cancer. Expert Opin Ther Targets. 2010 Jul;14(7):681-92 Cohen V, Agulnik JS, Ang C, Kasymjanova G, Batist G, Small D, Brandao G, Chong G, Miller WH Jr. Epidermal growth factor receptor mutations detected by denaturing high-performance liquid chromatography in nonsmall cell lung cancer: impact on response to therapy with epidermal growth factor receptor-tyrosine kinase inhibitors. Cancer Jun. 14. Alan Spatz, Batist G, Alexander M.M. Eggermont.
The Biology behind Progrnostic Factors of Cutaneous Melanoma. Curr Opin Oncol. 2010 May:22(3):163-8. Review Puts MT, Monette J, Girre V, Pepe C, Monette M, Assouline S, Panasci L, Basik M, Miller WH Jr, Batist G, Wolfson C, Bergman H.
Are frailty markers useful for predicting treatment toxicity and mortality in older newly diagnosed cancer patients? Results from a prospective pilot study. Crit Rev Oncol Hematol. 2010 May 3. Wu, J.H., Miao, W.M.; Hu, L.G., Batist, G.
Identification and characterization of novel Nrf2-inducers designed to target the intervening region of Keap1. CHEMICAL BIOL DRUG DES. 2010 May;75(5):475-80. Puts MT, Monette J, Girre V, Wolfson C, Monette M, Batist G, Bergman H.
Characteristics of older newly diagnosed cancer patients refusing cancer treatments. Support Care Cancer. 2010 Apr 25. Wan-Chow-Wah D, Monette J, Monette M, Sourial N, Retornaz F, Batist G, Puts MT, Bergman H. Difficulties in decision making regarding chemotherapy for older cancer patients: A census of cancer physicians. Crit Rev Oncol Hematol. 2010 Mar 22 Liangao Hu, Weimin Miao, Martin Loignon, Mustapha Kandouz, Batist G. Putative chemopreventive molecules can increase Nrf2-regulated cell defense in some human cancer cell lines, resulting in resistance to common cytotoxic therapies. Cancer Chemother Pharmacol. 2010 Aug;66(3):467-74. Epub 2009 Nov 26 |
|
(514) 340-8222 X 5418